Aarti Drugs

Why is Aarti Drugs Ltd falling/rising?

As of 24-Jun, Aarti Drugs Ltd's stock price is at 372.40, reflecting a decline of -0.65%. The stock has consistently underperformed against benchmarks, with a significant drop of -14.86% over the past year and -47.53% over five years, amid concerns about long-term growth and financial metrics.

As of 24-Jun, Aarti Drugs Ltd's stock price is falling, currently at 372.40, reflecting a change of -2.45 (-0.65%). The stock has been underperforming, having lost -0.9% over the last two days and showing a negative performance of -4.39% over the past month, while the benchmark Sensex has gained 2.09% in the same period. <BR><BR>In terms of longer-term performance, the stock has generated a return of -14.86% over the past year and has consistently underperformed against the benchmark over the last three years. This trend is further highlighted by a significant decline of -47.53% over the past five years compared to a 46.10% increase in the Sensex. <BR><BR>Despite some positive indicators, such as rising investor participation with a delivery volume increase of 93.74% against the five-day average, the overall sentiment remains negative due to poor long-term growth, as evidenced by an annual operating profit decline of -8.96% over the last five years. Additionally, the company's financial metrics, including a low return on capital employed (ROCE) of 11.4 and a debt to equity ratio of 0.45, contribute to concerns about its growth prospects. <BR><BR>Overall, the combination of recent price declines, underperformance relative to benchmarks, and weak long-term growth indicators are driving the stock's current downward trend.

Which are the latest news on Aarti Drugs?

How big is Aarti Drugs?

As of 10th June, Aarti Drugs Ltd has a market capitalization of 3,439.00 Cr, with recent Net Sales of 2,565.31 Cr and a Net Profit of 194.92 Cr.

As of 10th June, Aarti Drugs Ltd has a market capitalization of 3,439.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Aarti Drugs reported Net Sales of 2,565.31 Cr and a Net Profit of 194.92 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, showing Shareholder's Funds of 1,369.00 Cr and Total Assets of 2,574.68 Cr.

Who are in the management team of Aarti Drugs?

The management team of Aarti Drugs includes Prakash M Patil (Chairman and Managing Director), Rashesh C Gogri (Managing Director), Harshit M Savla (Joint Managing Director), and several other executive and independent directors, all contributing to the company's strategic direction.

The management team of Aarti Drugs includes the following key individuals:<BR><BR>1. **Prakash M Patil** - Chairman and Managing Director (CMD) & Executive Director<BR>2. **Rashesh C Gogri** - Executive Director (ED) / Managing Director (MD) / Promoter<BR>3. **Harshit M Savla** - Executive Director (ED) / Joint Managing Director (Joint MD) / Promoter<BR>4. **Harit P Shah** - Executive Director (ED) & Wholetime Director<BR>5. **Uday M Patil** - Wholetime Director (WTD) & Executive Director<BR>6. **Narendra Jagannath Salvi** - Non-Executive Director<BR>7. **Navin Chapshi Shah** - Independent Non-Executive Director<BR>8. **Krishnacharya G Akamanchi** - Independent Non-Executive Director<BR>9. **Priti Savla** - Independent Non-Executive Director<BR>10. **Ankit Vikram Paleja** - Independent Non-Executive Director<BR>11. **Bhaskar Narayan Thorat** - Independent Non-Executive Director<BR>12. **Neha Gada** - Independent Non-Executive Director<BR><BR>This team plays a crucial role in the strategic direction and management of the company.

Who are the peers of the Aarti Drugs?

Aarti Drugs' peers include IOL Chemicals, RPG LifeScience, Gufic BioScience, SMS Pharma, Unichem Labs, Panacea Biotec, Novartis India, Solara Active, Dishman Carbogen, and Morepen Labs. Novartis India leads in 1-year returns at 29.32%, while Aarti Drugs has a return of -21.25%.

Peers: The peers of Aarti Drugs are IOL Chemicals, RPG LifeScience, Gufic BioScience, SMS Pharma, Unichem Labs, Panacea Biotec, Novartis India, Solara Active, Dishman Carbogen, and Morepen Labs.<BR><BR>Quality Snapshot: Excellent management risk is observed at IOL Chemicals, RPG LifeScience, and Novartis India, while Average management risk is found at Gufic BioScience, SMS Pharma, Unichem Labs, Aarti Drugs, and Morepen Labs. Below Average management risk is noted at Panacea Biotec, Solara Active, and Dishman Carbogen. Growth is Good at Unichem Labs and Novartis India, while Below Average growth is seen at IOL Chemicals, RPG LifeScience, Gufic BioScience, SMS Pharma, Aarti Drugs, Panacea Biotec, Solara Active, and Morepen Labs. Average growth is noted for SMS Pharma and Gufic BioScience. Capital Structure is Excellent at IOL Chemicals and RPG LifeScience, Good at Unichem Labs and Aarti Drugs, and Average at Gufic BioScience and SMS Pharma, while Below Average is observed at Panacea Biotec, Solara Active, and Dishman Carbogen.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Novartis India at 29.32%, while Dishman Carbogen has the lowest at -38.27%. Aarti Drugs' own 1-year return is -21.25%, which is higher than Dishman Carbogen's but lower than Novartis India's. Additionally, the six-month return is negative for Dishman Carbogen and Solara Active.

What does Aarti Drugs do?

Aarti Drugs Ltd is a small-cap manufacturer of APIs, pharma intermediates, and specialty chemicals, with net sales of ₹720 Cr and a net profit of ₹55 Cr for the quarter ending March 2026. The company has a market cap of ₹3,439 Cr and key metrics include a P/E of 17.00 and a dividend yield of 0.54%.

Overview: <BR>Aarti Drugs Ltd is a prominent manufacturer of APIs, Pharma Intermediates, and Specialty Chemicals in the Pharmaceuticals & Biotechnology industry, categorized as a Small Cap company.<BR><BR>History: <BR>Aarti Drugs Limited was incorporated in September 1984. The latest quarterly results reported net sales and profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 720 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 55 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 3,439 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 17.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.54% <BR>Debt-Equity: 0.37 <BR>Return on Equity: 12.58% <BR>Price to Book: 2.20<BR><BR>Contact Details: <BR>Address: Plot No N-198 MIDC Tarapur, Pamtembhi Village Palghar Tal Thane Maharashtra : 401506 <BR>Tel: 91-22-24072249 <BR>Email: investorrelations@aartidrugs.com <BR>Website: http://www.aartidrugs.com

Should I buy, sell or hold Aarti Drugs Ltd?

Are Aarti Drugs Ltd latest results good or bad?

Aarti Drugs Ltd's latest results show strong revenue growth with a record ₹720.30 crores in Q4 FY26, but net profit declined 12.20% year-on-year to ₹55.19 crores, indicating ongoing profitability challenges despite some operational improvements. Investors should consider the mixed performance and underlying margin pressures.

Aarti Drugs Ltd's latest results present a mixed picture. On one hand, the company achieved its highest-ever quarterly revenue of ₹720.30 crores in Q4 FY26, reflecting a strong 19.71% growth compared to the previous quarter and a 6.43% increase year-on-year. This indicates robust operational momentum and strong demand recovery.<BR><BR>However, the net profit for the same quarter was ₹55.19 crores, which, while showing a significant 36.14% increase from the previous quarter, represents a 12.20% decline compared to the same quarter last year. This year-on-year drop highlights ongoing profitability challenges and margin pressures that the company has been facing.<BR><BR>The operating margin improved to 13.30%, up 420 basis points from the previous quarter, but it still fell short of the 13.79% margin achieved in Q4 FY25. This suggests that while there are positive signs of recovery, the company is still grappling with structural challenges that affect its profitability.<BR><BR>In summary, while Aarti Drugs has made notable strides in revenue growth and sequential profit recovery, the year-on-year decline in net profit and ongoing margin compression indicate that the company is still navigating significant hurdles. Investors may view the results as a cautious improvement but should remain aware of the underlying profitability concerns.

Has Aarti Drugs Ltd declared dividend?

Yes, Aarti Drugs Ltd has declared a dividend of 20% (₹1 per share) with an ex-date of February 9, 2026. Despite the dividend, the company's stock has experienced significant price declines over various periods, resulting in negative total returns.

Aarti Drugs Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 20%<BR>- Amount per share: 1 per share<BR>- Ex-date: 09 Feb 26<BR><BR>Dividend Yield: 0.27%.<BR><BR>Total Returns by Period:<BR>Over the last 3 months, the price return was -25.52%, the dividend return was 0.41%, resulting in a total return of -25.11%.<BR><BR>In the 6-month period, the price return was -22.09%, the dividend return was 0.41%, leading to a total return of -21.68%.<BR><BR>For the 1-year period, the price return was -9.88%, the dividend return was 0.49%, culminating in a total return of -9.39%.<BR><BR>Over the 2 years, the price return was -27.88%, the dividend return was 0.57%, resulting in a total return of -27.31%.<BR><BR>In the 3-year period, the price return was -10.63%, the dividend return was 1.10%, leading to a total return of -9.53%.<BR><BR>For the 4 years, the price return was -28.55%, the dividend return was 1.10%, culminating in a total return of -27.45%.<BR><BR>Over the last 5 years, the price return was -44.66%, the dividend return was 0.88%, resulting in a total return of -43.78%.<BR><BR>Overall, Aarti Drugs Ltd has declared a dividend, but the total returns over various periods indicate significant declines in price, with only modest contributions from dividends. This suggests that while dividends are being paid, the company's stock performance has been challenging.

When is the next results date for Aarti Drugs Ltd?

The next results date for Aarti Drugs Ltd is February 3, 2026.

The next results date for Aarti Drugs Ltd is scheduled for February 3, 2026.

Is Aarti Drugs technically bullish or bearish?

As of November 28, 2025, the market trend is neutral with mixed signals, showing a sideways movement influenced by conflicting indicators, including mildly bearish weekly MACD and Bollinger Bands, alongside mildly bullish daily moving averages.

As of 28 November 2025, the technical trend has changed from mildly bullish to sideways. The current technical stance is neutral, with mixed signals across different indicators. The weekly MACD is mildly bearish, while the monthly MACD is mildly bullish, indicating conflicting momentum. The Bollinger Bands are bearish on both weekly and monthly time frames, suggesting downward pressure. Daily moving averages are mildly bullish, providing some support. The KST is mildly bearish on the weekly and bearish on the monthly, while the Dow Theory shows a similar pattern with a mildly bearish weekly stance and mildly bullish monthly. Overall, the indicators reflect a lack of clear direction, reinforcing the sideways trend.

How has been the historical performance of Aarti Drugs?

Aarti Drugs has seen a decline in net sales and total operating income from INR 2,716.05 crore in March 2023 to INR 2,387.03 crore in March 2025, while profit after tax slightly increased from INR 166.36 crore to INR 168.10 crore during the same period. Total assets and liabilities rose, but cash flow from operating activities decreased significantly.

Answer:<BR>The historical performance of Aarti Drugs shows fluctuations in various financial metrics over the years.<BR><BR>Breakdown:<BR>Aarti Drugs' net sales have experienced a decline from INR 2,716.05 crore in March 2023 to INR 2,387.03 crore in March 2025. The total operating income followed a similar trend, decreasing from INR 2,716.05 crore in March 2023 to INR 2,387.03 crore in March 2025. The total expenditure, excluding depreciation, also decreased from INR 2,410.45 crore in March 2023 to INR 2,099.97 crore in March 2025, contributing to an operating profit (PBDIT) of INR 303.42 crore in March 2025, down from INR 307.79 crore in March 2023. Profit before tax showed a decline from INR 224.18 crore in March 2023 to INR 211.77 crore in March 2025, while profit after tax slightly increased from INR 166.36 crore in March 2023 to INR 168.10 crore in March 2025. The consolidated net profit also saw a minor increase from INR 166.31 crore in March 2023 to INR 168.16 crore in March 2025. On the balance sheet, total assets rose from INR 2,421.40 crore in March 2023 to INR 2,574.68 crore in March 2025, while total liabilities increased from INR 2,421.40 crore to INR 2,574.68 crore during the same period. Cash flow from operating activities decreased from INR 358.00 crore in March 2024 to INR 244.00 crore in March 2025, and the closing cash and cash equivalents dropped from INR 6.00 crore in March 2024 to INR 4.00 crore in March 2025.

Is Aarti Drugs overvalued or undervalued?

As of May 26, 2025, Aarti Drugs is considered undervalued with a PE ratio of 25.26 and a favorable valuation compared to peers like Sun Pharma and Divi's Lab, despite underperforming the Sensex over the past year but recently achieving a 1-month return of 11.43%.

As of 26 May 2025, Aarti Drugs has moved from a fair to an attractive valuation grade. The company is currently considered undervalued, with a PE ratio of 25.26, an EV to EBITDA ratio of 16.91, and a ROE of 12.28%. In comparison to its peers, Aarti Drugs' valuation is more favorable than Sun Pharma, which is deemed expensive with a PE of 35.25, and Divi's Lab, categorized as very expensive with a PE of 79.33.<BR><BR>The company's performance metrics suggest it is positioned well within the pharmaceuticals and biotechnology sector. Notably, Aarti Drugs has a PEG ratio of 0.00, indicating potential for growth relative to its price. While the stock has underperformed the Sensex over the past year, its recent 1-month return of 11.43% outpaces the Sensex's 3.88%, reinforcing the attractiveness of its valuation.

Who are the top shareholders of the Aarti Drugs?

The top shareholders of Aarti Drugs include promoter Prakash Moreshwar Patil with 9.32%, mutual funds with 8.75%, foreign institutional investors at 2.25%, and the DSP Small Cap Fund as the largest public shareholder at 7.13%. Individual investors collectively own 23.51% of the company.

The top shareholders of Aarti Drugs include the promoters, who hold the majority of the shares. The promoter with the highest holding is Prakash Moreshwar Patil, with a stake of 9.32%. Additionally, mutual funds hold 8.75% of the shares across seven schemes, while foreign institutional investors (FIIs) account for 2.25% through 80 different entities. The highest public shareholder is the DSP Small Cap Fund, which holds 7.13%. Individual investors collectively own 23.51% of the company.

What is the bonus history of the Aarti Drugs?

Aarti Drugs has a history of issuing bonuses to shareholders, with the most recent being a 3:1 bonus announced on September 30, 2020, and a previous 1:1 bonus issued on March 25, 2015.

Aarti Drugs has a history of issuing bonuses to its shareholders. The most recent bonus was a 3:1 issue, which was announced with an ex-date of September 30, 2020, and a record date of October 1, 2020. Prior to that, the company issued a 1:1 bonus on March 25, 2015, with an ex-date of March 24, 2015. This indicates that Aarti Drugs has actively engaged in rewarding its shareholders through bonus shares over the years.